Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:54 AM
Ignite Modification Date:
2025-12-25 @ 4:54 AM
NCT ID:
NCT03248518
Eligibility Criteria:
Inclusion Criteria:
* be ≥ 18 years at the time of consent
* have been diagnosed with rheumatoid arthritis (RA), systemic lupus erythematous (SLE), axial spondyloarthritis (AxSpA) or psoriatic arthritis (PSA) by a rheumatologist
* report fatigue to be a persistent problem
* have access to a telephone landline or mobile telephone and/or internet based audio/video calls
* give permission for researchers to access their hospital medical notes
* currently be under the care of a secondary care physician
* have stable disease as evidenced by no change in immunomodulatory therapy within the last three months based on the hospital medical record
Exclusion Criteria:
* there are significant abnormalities of thyroid function (TSH levels) on the most recent blood test done within the last three months
* there is evidence of severe anaemia (haemoglobin levels) on the most recent blood test done within the last three months
* there is evidence of severe renal dysfunction (eGFR) on the most recent blood test done within the last three months
* they have a medical condition which would make the proposed interventions unsuitable, e.g. significant heart disease
* they are pregnant
* they are unable to understand English sufficiently to take part in the intervention
* they are unable to provide written informed consent
* they are not willing to be randomised
* they are currently participating in an interventional clinical trial
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03248518
Study Brief:
Protocol Section:
NCT03248518